Table 1 Demographics and clinical characteristics within each racial/ethnic group of advanced patients with NSCLC treated with osimertinib
All patients (n = 174) | Non-Hispanic Whites (n = 46, 26.4%) | Non-Hispanic Blacks (n = 50, 28.7%) | Hispanics (n = 56, 32.2%) | Asian (n = 22, 12.6%) | P value | ||
|---|---|---|---|---|---|---|---|
Age at start of osimertinib (years, median, range) | 69 (30–92) | 72.50 (46–89) | 67.5 (30–88) | 69 (32–90) | 67 (42–92) | 0.483 | |
Gender, n (%) | Male | 53 (30.5) | 11 (23.9) | 13 (26.0) | 20 (35.7) | 9 (40.9) | 0.353 |
Female | 121 (69.5) | 35 (76.1) | 37 (74.0) | 36 (64.3) | 13 (59.1) | ||
Smoking, n (%) | Smoker (former or active) | 77 (44.3) | 31 (67.4) | 22 (44.0) | 20 (35.7) | 4 (18.2) | 0.001 |
Never smoker | 97 (55.7) | 15 (32.6) | 28 (56.0) | 36 (64.3) | 18 (81.8) | ||
Weight (kg, median, range) | 63.8 (34–128) | 58.3 (34–115) | 69.5 (39.6–128) | 63.6 (37.9–97.0) | 58.4 (37.9–85.7) | 0.002 | |
BMI (kg/m2, median, range) | 23.9 (12.4–45.6) | 22.2 (12.4–37.4) | 25.2 (14.2–45.6) | 24.9 (15.8–38.0) | 22.4 (16.1–33.5) | 0.011 | |
< 18.5 | 21 (12.1) | 8 (17.4) | 6 (12.0) | 3 (5.4) | 4 (18.2) | 0.105 | |
18.5–25 | 81 (46.6) | 26 (56.5) | 18 (36.0) | 27 (48.2) | 10 (45.5) | ||
>25 | 72 (41.4) | 12 (26.1) | 26 (52.0) | 26 (46.4) | 8 (36.4) | ||
Insurance (%) | Commercial | 38 (21.8) | 13 (28.3) | 14 (28.0) | 6 (10.7) | 5 (22.7) | 0.025 |
Medicare | 95 (54.6) | 29 (63.0) | 20 (40.0) | 36 (64.3) | 10 (45.5) | ||
Medicaid | 35 (20.1) | 4 (8.7) | 12 (24.0) | 12 (21.4) | 7 (31.8) | ||
Medicare and Medicaid | 6 (3.4) | 0 (0.0) | 4 (8.0) | 2 (3.6) | 0 (0.0) | ||
Household income (USD) by Zip Code (median, range) | 56,279 (23,337–243,514) | 88,795 (37,886–243,514) | 47,831 (23,337–97,919) | 37,886 (23,337–215,797) | 56,410 (35,813–114,698) | <0.001 | |
<$50,000 | 82 (47.1) | 4 (8.7) | 27 (54.0) | 42 (75.0) | 9 (40.9) | <0.001 | |
≥$50,000 | 92 (52.9) | 42 (91.3) | 23 (46.0) | 14 (25.0) | 13 (59.1) | ||
Actual out-of-pocket costa (USD, mean) | 59.3 | 78.3 | 2.6 | 116.1 | 6.0 | 0.756 | |
Not available (%) | 111 (63.8) | 38 (82.6) | 26 (52.0) | 30 (53.6) | 17 (77.3) | ||
Total costa (USD, median) | 16,734 | 16,734 | 16,734 | 16,734 | 16,734 | 0.804 | |
Not available (%) | 111 (63.8) | 38 (82.6) | 26 (52.0) | 30 (53.6) | 17 (77.3) | ||
Adherent to osimertinib (PDC ≥ 80%) | Yes | 62 (35.6) | 10 (21.7) | 20 (40.0) | 24 (42.9) | 8 (36.4) | 0.412 |
No | 14 (8.0) | 2 (4.3) | 7 (14.0) | 5 (8.9) | 0 (0.0) | ||
Not available | 98 (56.3) | 34 (73.9) | 23 (46.0) | 27 (48.2) | 14 (63.6) | ||
ECOG at start of osimertinib, n (%) | <2 | 129 (74.1) | 36 (78.3) | 36 (72.0) | 43 (76.8) | 14 (63.6) | 0.573 |
≥2 | 45 (25.9) | 10 (21.7) | 14 (28.0) | 13 (23.2) | 8 (36.4) | ||
Brain metastasis, n (%) | Yes | 69 (39.7) | 14 (30.4) | 19 (38.0) | 23 (41.1) | 13 (59.1) | 0.157 |
No | 105 (60.3) | 32 (69.6) | 31 (62.0) | 33 (58.9) | 9 (40.9) | ||
Histology, n (%) | Adenocarcinoma | 168 (96.6) | 46 (100.0) | 48 (96.0) | 54 (96.4) | 20 (90.9) | 0.284 |
Squamous | 6 (3.4) | 0 (0.0) | 2 (4.0) | 2 (3.6) | 2 (9.1) | ||
TRAEs present, n (%) | Yes | 100 (57.5) | 26 (56.5) | 26 (52.0) | 36 (64.3) | 12 (54.5) | 0.621 |
No | 74 (42.5) | 20 (43.5) | 24 (48.0) | 20 (35.7) | 10 (45.5) | ||
Initial EGFR mutation at diagnosis | del19 | 110 (63.2) | 26 (56.5) | 34 (68.0) | 39 (69.6) | 11 (50.0) | 0.272 |
L858R | 45 (25.9) | 12 (26.1) | 10 (20.0) | 14 (25.0) | 9 (40.9) | ||
Uncommonb | 19 (10.9) | 8 (17.4) | 6 (12.0) | 3 (5.4) | 2 (9.1) | ||
Prior EGFR TKI (other than osimertinib) | Yes | 49 (28.2) | 16 (34.8) | 11 (22.0) | 17 (30.4) | 5 (22.7) | 0.496 |
No | 125 (71.8) | 30 (65.2) | 39 (78.0) | 39 (69.6) | 17 (77.3) | ||
Prior chemotherapy | Yes | 31 (17.8) | 9 (19.6) | 6 (12.0) | 12 (21.4) | 4 (18.2) | 0.625 |
No | 143 (82.2) | 37 (80.4) | 44 (88.0) | 44 (78.6) | 18 (81.8) | ||
Lines of therapy with osimertinib | First line | 111 (63.8) | 25 (54.3) | 38 (76.0) | 33 (58.9) | 15 (68.2) | 0.124 |
Second line or beyond | 63 (36.2) | 21 (45.7) | 12 (24.0) | 23 (41.1) | 7 (31.8) |
